Real‑World “Time Toxicity” and Patient Impact: Lessons from ASH 2025 for Epcoritamab in Follicular Lymphoma

EP: 1.Introduction and Exploring the Financial Burden of Follicular Lymphoma

EP: 2.Optimizing First- and Second-Line Treatment Strategies in Follicular Lymphoma

EP: 3.Advancing Care in Relapsed/Refractory Follicular Lymphoma Beyond Chemotherapy

EP: 4.Integrating Bispecific Antibodies and Evolving Strategies in Relapsed/Refractory Follicular Lymphoma

EP: 5.Implications of the RELEVANCE Study and Optimal Use of R² in Second-Line Follicular Lymphoma

EP: 6.Targeted Therapies and Bispecific Antibodies in Second-Line Follicular Lymphoma

EP: 7.Epcoritamab Maintenance and Quality of Life Considerations in Follicular Lymphoma

Now Viewing

EP: 8.Real‑World “Time Toxicity” and Patient Impact: Lessons from ASH 2025 for Epcoritamab in Follicular Lymphoma

EP: 9.Operational Challenges and Solutions for Implementing Bispecific Antibodies in Follicular Lymphoma

A recent real‑world analysis presented at American Society of Hematology Annual Meeting (ASH 2025) examined “time toxicity” — the burden of frequent healthcare visits and therapy‑related appointments — in patients treated with Epcoritamab. The study compared fixed‑duration regimens (such as for some bispecific antibodies) to continuous, treat‑to‑progression approaches, such as CAR-T therapies.